All news

22 October 2026

Moderna sinks as much as 25% after a cancer vaccine data leak, despite solid results

Partial results for Moderna and Merck's personalized melanoma vaccine leaked on Thursday. The full data looked positive, but the stock had risen more than 530% this year.

Sometimes good news is not good enough. Moderna shares fell as much as 25% on Thursday after partial results from its cancer vaccine trial with Merck leaked ahead of schedule, even though the full numbers, published later that day, looked like a win for patients.

What happened

The vaccine, called intismeran autogene, is made for each patient. It is designed around the specific mutations in that person's tumor, training the immune system to find and kill those cells. It is given with Keytruda, Merck's big-selling immunotherapy, a drug that helps the body's own defenses attack cancer.

In a phase 3 trial, the large final stage of testing, the combination beat Keytruda alone in certain melanoma patients:

  • 42% lower risk of the cancer coming back or the patient dying.
  • 38% lower risk of the cancer spreading to distant parts of the body, or death.
  • About 82% were alive with no melanoma return after two years, versus 70% on Keytruda alone.
  • A separate analysis after the six-month vaccine course showed a 58% lower risk of recurrence or death.

The companies say it is too early to know whether patients live longer overall. A trial investigator at MD Anderson Cancer Center said side effects were much milder than with other cancer treatments, mainly things like soreness where the shot goes in. Detailed results are due at the European Society for Medical Oncology (ESMO) conference this weekend.

Why it matters

The fall was about expectations as much as data. Moderna stock was up more than 530% this year as of Thursday afternoon, so investors had already priced in a lot. Analysts at BMO Capital Markets and UBS both called the results positive and said the reaction seemed to reflect inflated expectations rather than weak data.

The stakes are big for Moderna. Over the last twelve months it reported about $2.2 billion of revenue and a net loss of roughly $3.2 billion, according to its filings via Noorult, and it was valued at about $97 billion on October 20. A cancer product would join its vaccines for Covid-19, flu and RSV. Merck, worth about $366 billion, slipped around 1% on Thursday; its stock is up nearly 41% this year.

What to watch

Merck's research chief, Dean Li, stressed that one result is only a start: "Knocking one tree does not give you a cabin or a village."

  • The full ESMO presentation this weekend.
  • Trials in other cancers, including non-small cell lung, bladder and kidney cancer.
  • Manufacturing time: each shot takes about six weeks to make, and Merck's CEO has said the company believes it can shorten that.

Financials for both drugmakers are on Noorult: Moderna and Merck.

The companies in this story

Based on reporting by CNBC: Moderna stock falls after cancer vaccine data leak. Facts, not advice.

More news